Cytokinetics, Incorporated (NASDAQ:CYTK) Director John T. Henderson Sells 3,190 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK) Director John T. Henderson sold 3,190 shares of Cytokinetics stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $38.66, for a total transaction of $123,325.40. Following the transaction, the director now directly owns 66,348 shares in the company, valued at $2,565,013.68. This represents a 4.59 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Cytokinetics Stock Performance

Cytokinetics stock opened at $39.15 on Thursday. The company has a debt-to-equity ratio of 5.93, a quick ratio of 9.28 and a current ratio of 9.28. The company has a market capitalization of $4.67 billion, a PE ratio of -7.28 and a beta of 0.94. The company has a 50 day moving average price of $42.73 and a 200-day moving average price of $47.93. Cytokinetics, Incorporated has a fifty-two week low of $32.74 and a fifty-two week high of $69.90.

Cytokinetics (NASDAQ:CYTK) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.03. The firm had revenue of $16.93 million for the quarter, compared to the consensus estimate of $14.26 million. As a group, equities analysts forecast that Cytokinetics, Incorporated will post -5.24 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages have issued reports on CYTK. Citigroup initiated coverage on shares of Cytokinetics in a report on Friday, February 7th. They set a “buy” rating and a $86.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $120.00 target price on shares of Cytokinetics in a research note on Tuesday. Royal Bank of Canada boosted their price target on shares of Cytokinetics from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 18th. Bank of America cut their price objective on Cytokinetics from $62.00 to $54.00 and set a “neutral” rating for the company in a research report on Tuesday. Finally, Stifel Nicolaus began coverage on Cytokinetics in a research report on Wednesday, January 22nd. They issued a “buy” rating and a $80.00 target price on the stock. Two analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Cytokinetics has an average rating of “Moderate Buy” and an average price target of $81.63.

Institutional Trading of Cytokinetics

A number of hedge funds have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp increased its position in Cytokinetics by 189.8% during the 4th quarter. Jones Financial Companies Lllp now owns 571 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 374 shares during the period. Centricity Wealth Management LLC purchased a new stake in Cytokinetics during the fourth quarter worth $29,000. Fifth Third Bancorp boosted its position in Cytokinetics by 42.2% during the 1st quarter. Fifth Third Bancorp now owns 981 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 291 shares in the last quarter. Parallel Advisors LLC increased its holdings in shares of Cytokinetics by 500.5% in the 1st quarter. Parallel Advisors LLC now owns 1,099 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 916 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of Cytokinetics by 281.0% in the 1st quarter. GAMMA Investing LLC now owns 1,120 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 826 shares in the last quarter.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.